Company Description
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia.
The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease.
Incannex Healthcare Inc. is headquartered in Sydney, Australia.
| Country | Australia |
| Founded | 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Joel Latham |
Contact Details
Address: 8 Century Circuit, Suite 105 Sydney, NSW 2153 Australia | |
| Phone | 61 4 0984 0786 |
| Website | incannex.com |
Stock Details
| Ticker Symbol | IXHL |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $9.38 |
| CIK Code | 0001873875 |
| CUSIP Number | 45333L106 |
| ISIN Number | US45333F1093 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michailidis B.Sc., EMBA, M.A.I.C.D. | Chief Executive Officer of IncannexTM |
| Joel Bradley Latham | President, Chief Executive Officer and Executive Director |
| Joseph Swan | Chief Financial Officer, Treasurer and Secretary |
| Lekhram Changoer M.Sc. | Chief Technology Officer and Member of Advisory Board |
| Natalie May | Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | ARS | Filing |
| Nov 12, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 6, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 6, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 31, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 8-K | Current Report |